SoCal's Kite Pharma Grabs a Clinical Trial Cancer Deal with Genentech

Published: Mar 17, 2016

Kite Pharma, Inc. (Nasdaq: KITE) announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group (OTC: RHHBY), to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab (also known as MPDL3280A), in patients with refractory, aggressive non-Hodgkin lymphoma (NHL).

KTE-C19 is an investigational immunotherapy in which a patient's T cells are genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Atezolizumab is an investigational monoclonal antibody designed to target and bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells.

Back to news